Elvitegravir / Cobicistat / Emtricitabin / Tenofoviralafenamid (2) – Genvoya®

HIV infection, 6 to < 12 years

Characteristics

Start date 15.01.2018 – Marketing authorisation: 08.12.2017
Resolution 05.07.2018
INN Elvitegravir/Cobicistat/Emtricitabin/Tenofoviralafenamid
Brand name Genvoya®
Pharm. company Gilead Sciences GmbH
G-BA Procedure ID D-334
ATC code J05AR18 Antivirals for treatment of HIV infections, combinations (J05AR)
DDD 1 U O
Therapeutic area Infectious diseases
Reason for procedure New therapeutic indication
Specialty ACT change

Studies and Results

  • Clinical trials
    • No data were submitted to assess the additional benefit of elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide compared with the appropriate comparator therapy.

a) HIV-1-infected children aged ≥ 6 years to < 12 years who have not previously received antiretroviral treatment

  • The additional benefit is not proven.
  • No data were submitted to assess the additional benefit of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide compared with the appropriate comparator therapy.

b) HIV-1-infected children aged ≥ 6 years to < 12 years who have received prior antiretroviral treatment

  • The additional benefit is not proven.
  • No data have been submitted to assess the additional benefit of elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide compared with the appropriate comparator therapy.

Courtesy translation only, please refer to the German original.

Associated procedures



<< List of all resolutions